Trial Profile
A Phase 2A Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Trial of PQ912 in Subjects with early Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2022
Price :
$35
*
At a glance
- Drugs Varoglutamstat (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms SAPHIR; SAPHIR 1; SAPHIR-tutkimus
- Sponsors Probiodrug; Vivoryon Therapeutics
- 16 Oct 2018 According to a Probiodrug media release, data from this trial has been published in the journal Alzheimer's Research & Therapy.
- 30 Aug 2018 According to a Probiodrug media release, data from this trial was presented at the 255th National Meeting & Exposition of the American Chemical Society (ACS) (Mar 2018).
- 30 Nov 2017 According to a Probiodrug media release, data from the study has been presented in November 2017 at Clinical Trials on Alzheimer's Disease (CTAD) 2017 Conference.